{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:21:02Z","timestamp":1770506462519,"version":"3.49.0"},"reference-count":10,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,4,6]],"date-time":"2005-04-06T00:00:00Z","timestamp":1112745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:title>Abstract:<\/jats:title><jats:p><jats:bold>Background: <\/jats:bold> Conventional treatment of autoimmune hepatitis consists of either prednisone alone or in combination with azathioprine. Ten to 20% of patients do not respond to or are intolerant of this treatment. Novel drug treatments include immunosuppressive drugs such as tacrolimus (TAC), mycophenolate mofetil (MMF), methotrexate and cyclosporine. We describe a multi\u2010centre Canadian experience with MMF and TAC.<\/jats:p><jats:p><jats:bold>Objective: <\/jats:bold> To study a multi\u2010centre patient population who had failed conventional therapy and were treated with non\u2010conventional medical therapy for autoimmune hepatitis and document response.<\/jats:p><jats:p><jats:bold>Methods: <\/jats:bold> Members of the Canadian Association for the Study of Liver (CASL) obtained MMF from Hoffmann\u2010La Roche Ltd, as part of a compassionate release program, were contacted for standardized data on patients with AIH who received MMF or TAC. Response definitions based on aminotransferase changes were: Complete response (CR)\u2010sustained normalization, partial response (PR)\u2010improvement by greater than 50%, non\u2010response (NR)\u2010less than 50% improvement and relapse (RP)\u2010initial CR or PR followed by an increase in aminotransferases.<\/jats:p><jats:p><jats:bold>Results: <\/jats:bold> A total of 16 patients were identified: six in Ontario, one in Quebec, five in Alberta and four in British Columbia. Three were treated with TAC, eleven with MMF and two with combination MMF and TAC. CR was observed in 50%, PR in 12.5%, RP in 25% and NR occurred in 12.5%. The CR for MMF without TAC was approximately 64%.<\/jats:p><jats:p><jats:bold>Conclusions: <\/jats:bold> MMF is effective and well tolerated by patients with autoimmune hepatitis who do not respond to, or are intolerant of, conventional immunosuppressive agents.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2005.01107.x","type":"journal-article","created":{"date-parts":[[2005,7,5]],"date-time":"2005-07-05T18:53:21Z","timestamp":1120589601000},"page":"723-727","source":"Crossref","is-referenced-by-count":91,"title":["Transplant immunosuppressive agents in non\u2010transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus"],"prefix":"10.1111","volume":"25","author":[{"given":"Nazira","family":"Chatur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alnoor","family":"Ramji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent G.","family":"Bain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mang M.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Marotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron N.","family":"Ghent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie B.","family":"Lilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Jenny","family":"Heathcote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Deschenes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urs P.","family":"Steinbrecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,6,8]]},"reference":[{"issue":"3","key":"e_1_2_7_2_2","first-page":"511","article-title":"Treatment strategies in autoimmune hepatitis","volume":"6","author":"Czaja A.","year":"2002","journal-title":"Clin Liver Disease"},{"issue":"3","key":"e_1_2_7_3_2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1089-3261(02)00029-6","article-title":"Evolving new therapies of autoimmune hepatitis","volume":"6","author":"Vierling J M","year":"2002","journal-title":"Clin Liver Disease"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.00807.x"},{"key":"e_1_2_7_5_2","first-page":"771","article-title":"Tacrolimus","volume":"90","author":"Van Theil D H","year":"1995","journal-title":"a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v110.pm8536867"},{"key":"e_1_2_7_7_2","first-page":"571","article-title":"Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis \u2013 report of three cases","volume":"35","author":"Kanzler C","year":"1997","journal-title":"Z Gastroenterol"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80271-8"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1155\/2004\/504591"},{"key":"e_1_2_7_10_2","first-page":"929","article-title":"International Autoimmune Hepatitis Group Report","volume":"31","author":"Alvarez F","year":"1999","journal-title":"review of criteria for diagnosis of autoimmune hepatitis"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10310-X"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2005.01107.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2005.01107.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T12:18:22Z","timestamp":1697285902000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2005.01107.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,8]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1111\/j.1478-3231.2005.01107.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2005.01107.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,8]]}}}